PRESENTATION

Q3 2023 — Presentation

Q3 2023PDF · 31 pages2.0 MB
Merck
Q3 2023 Earnings
October 26, 2023

-- 1 of 31 --

Agenda
2
Strategy and
Business Update
Rob Davis
Chairman and Chief
Executive Officer
Question & Answer
Session
Business/Financial
Results and Outlook
Caroline Litchfield
Chief Financial Officer
Research
Update
Dr. Dean Li
President, Merck
Research Laboratories

-- 2 of 31 --

Forward-looking statement of Merck & Co., Inc.,
Rahway, N.J., USA
3
This presentation of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of
the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and
are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary
regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual
results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency
exchange rate fluctuations; the impact of the global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health
care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents
attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future
market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the
company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report
on Form 10-K for the year ended December 31, 2022 and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s
Internet site (www.sec.gov).

-- 3 of 31 --

Strategy and
Business Update
Rob Davis
Chairman and Chief Executive Officer

-- 4 of 31 --

Delivered on our key strategic priorities in Q3 2023
5
Advanced the pipeline to meet
patient unmet need
Achieved strong commercial and
financial performance
Executed on strategic business
development to augment pipeline
Created long-term value for patients
and shareholders
&

-- 5 of 31 --

2021 	2022 	2023
Strong Q3 sales performance and earnings growth 1
6
1. Results from continuing operations attributable to Merck & Co., Inc. 2. Excludes Lagevrio sales of $640 million in 3Q23 and $436 million in 3Q22. 3. Merck does not exclude expenses for upfront and milestone payments
related to collaborations and licensing agreements, or charges related to pre-approval assets obtained in transactions accounted for as asset acquisitions from its non-GAAP results. YTD 2023 non-GAAP results include an
aggregate $11.6 billion or $4.52 per share of R&D expenses related to the Prometheus and Imago acquisitions and upfront payment for the license and collaboration agreement with Kelun-Biotech. Full year 2022 non-GAAP
results include $690 million or $0.22 of such charges. Full year 2021 non-GAAP results include $1.7 billion or $0.65 of such charges. For 2023, guidance includes an additional $5.5 billion or $1.70 per share related to the
collaboration with Daiichi Sankyo, and guidance does not assume any additional significant potential business development transactions. 4. GAAP EPS of $1.86.
$16.0B
+7%
+8% ex-Exchange, ex-LAGEVRIO
2
Q3 Worldwide Sales
$2.13
+15%
Q3 Non-GAAP EPS3,4
$48.7B
+17%
$5.37
Full Year Sales
Full Year Non-GAAP EPS3
$59.3B
+22%
GUIDANCE RANGE
$59.7B - $60.2B
2021 	2022 	2023
GUIDANCE RANGE
$1.33 - $1.38
$5.37
$7.48

-- 6 of 31 --

Oncology Highlights 	Cardiometabolic Highlights
• 	KEYNOTE-671: Received FDA approval for KEYTRUDA
for the neoadjuvant and adjuvant treatment of certain
patients with resectable non-small cell lung cancer
• 	ESMO: Compelling data presented across a wide range
of molecules, tumor types and indications
• 	Sotatercept: FDA accepted for priority review the BLA
for sotatercept for the treatment of adults with
pulmonary arterial hypertension based on STELLAR
• 	MK-0616: Started Phase 3 program for oral PCSK9
inhibitor candidate
7
Advancing and enhancing our deep pipeline

-- 7 of 31 --

Continuing to deliver on our purpose for patients
8
$4.2B
+20%
$3.4B
+31%
$5.3B
+30%
$4.8B
+27%
$5.8B
+24%
Pursuing
transformative
science to save
and improve lives
around the world

-- 8 of 31 --

Business/Financial
Results and Outlook
Caroline Litchfield
Chief Financial Officer

-- 9 of 31 --

Strong underlying Q3 worldwide sales growth
10
Merck
WORLDWIDE SALES1,2
$16.0B+7% growth
+6% ex-LAGEVRIO3
+8% ex-exchange, ex-LAGEVRIO3
$14.3B
+10% growth
+9% ex-LAGEVRIO3
+10% ex-exchange, ex-LAGEVRIO3
Human Health
$1.4B
+2% growth
+2% ex-exchange
Animal Health
1. Results attributable to Merck & Co., Inc. 2. Worldwide Sales includes Other Revenue. 3. Excludes Lagevrio sales of $640 million in 3Q23 and $436 million in 3Q22.

-- 10 of 31 --

Oncology: KEYTRUDA continues to drive exceptional growth
11	Growth rates exclude the impact of foreign exchange.
• KEYTRUDA sales of $6.3B increased 17%
year-over-year, driven by global uptake in
earlier stage cancers and continued strong
global demand from metastatic indications
– In the U.S., growth of 14% reflects strong
utilization across metastatic indications and
earlier stage cancers, such as TNBC
– Ex-U.S., 22% increase driven by uptake in
earlier stage cancers, including high-risk early-
stage TNBC and adjuvant RCC, as well as
increased demand in advanced RCC and
certain types of H&N cancer
$4.2B
+20%
$3.4B
+31%
$5.3B
+30%
3Q21 	3Q22 	3Q23
$5.4B
+26%
$4.5B
+21%
$6.3B
+17%

-- 11 of 31 --

Oncology: Solid performance across broad portfolio
• Lynparza 1 sales grew 6% driven primarily by
pricing in the U.S. and increased demand in
Latin America
• Lenvima 2 sales grew 30% driven by timing
of shipments in China and increased demand
in advanced RCC and endometrial cancer
indications in the U.S.
$248M
+34%	$178M
+62%
$275M
+17%
$181M
+15%
$151M
+57%
$231M
+33%
12	Growth rates exclude the impact of foreign exchange.
1. In collaboration with AstraZeneca 2. In collaboration with Eisai
3Q21 	3Q22 	3Q23
3Q21 	3Q22 	3Q23
$284M
+23%$246M
+25%
$299M
+6%
$202M
+11%
$188M
+30%
$260M
+30%

-- 12 of 31 --

Vaccines: Robust growth driven by GARDASIL
13
• GARDASIL sales of $2.6B increased 16%
year-over-year driven by strong demand,
particularly in China
– In the U.S., sales decreased due to the
timing of CDC purchases
• Strong uptake of the pediatric indication
of VAXNEUVANCE in the U.S. and
launches in key European markets $1.2B
+78%
$656M
-24%
$1.7B
+40%
3Q21 	3Q22 	3Q23
$2.3B
+20%$2.0B
+63%
$2.6B
+16%
Growth rates exclude the impact of foreign exchange.

-- 13 of 31 --

Hospital: Contributions from key products
14
• BRIDION sales of $424M were flat as
greater share among neuromuscular
blockade reversal agents in the U.S. was
offset by the impact of generic entry
primarily in Europe
• PREVYMIS sales grew 38% driven by
continued strong global demand
$387M
+67%
$224M
-18%
$426M
+15%
3Q21 	3Q22 	3Q23
$423M
+22%	$369M
+15%
$424M
+0%
$93M
+41%$63M
+67%
$103M
+18%
$94M
+20%
$82M
+31%
$129M
+44%
Growth rates exclude the impact of foreign exchange.
3Q21 	3Q22 	3Q23
$114M
+29%
$96M
+22%
$157M
+38%

-- 14 of 31 --

Animal Health: Growth driven by livestock
15
• Animal Health sales increased 2% to $1.4B
– Livestock growth of 7% reflects price actions
and increased demand for ruminant, poultry
and swine products
– Companion Animal sales declined 4% due to a
reduction in vet visits in the U.S., partially
offset by pricing actions $1.5B
+27%
$1.1B
+3%
$1.5B
+5%
3Q21 	3Q22 	3Q23
$1.4B
+4%
$1.4B
+14%
$1.4B
+2%
Growth rates exclude the impact of foreign exchange.

-- 15 of 31 --

Q3 2023 non-GAAP financial results summary 1
Q3 2023 	Q3 2022 	Change Change
Ex-FX
Sales 	$16.0 	$15.0 	+7% 	+9%
Non-GAAP Gross Margin 	77.0% 	77.0% 	-0.1pts 	+0.8pts
Non-GAAP Operating
Expenses $5.8 	$6.0 	-4% 	-3%
Non-GAAP Tax Rate 	15.0% 	13.6% 	+1.4pts 	N/A
Non-GAAP EPS2,3 $2.13 	$1.85 	+15% 	+22%
$ in billions, except EPS amounts
16
1. Merck is providing certain 2023 and 2022 non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business
performance and trends. Management believes that providing this information enhances investors’ understanding of the company’s results because management uses non-GAAP results to assess
performance. Management uses non-GAAP measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, senior
management’s annual compensation is derived in part using a non-GAAP pre-tax income metric. This information should be considered in addition to, but not as a substitute for or superior to,
information prepared in accordance with GAAP. For a description of the non-GAAP adjustments, see Table 2a attached to the earnings release. 2. Q3 2022 includes $690 million of R&D expense for
collaborations and licensing agreements with Moderna, Orna and Orion, or $0.22 of negative impact to EPS. 3. Q3 2023 GAAP EPS of $1.86.

-- 16 of 31 --

Merck updated full-year 2023 guidance
1. Updated guidance includes an aggregate $17.1 billion of R&D expenses related to the Prometheus and Imago acquisitions, and upfront payments for the license and collaboration agreement with
Kelun-Biotech and collaboration agreement with Daiichi Sankyo. Guidance does not assume any additional significant potential business development transactions. 2. Updated guidance includes
$6.22 of one-time charges related to the Prometheus and Imago acquisitions and upfront payments to Kelun-Biotech and Daiichi Sankyo.
17
Prior Guidance 	Updated Guidance 	Key Assumptions
Revenue $58.6B to $59.6B
-1% to +1% (+1% to +3% ex-FX)
$59.7B to $60.2B
+1% to +2% (+3% to +4% ex-FX)
• 	Includes approximately $1.3B of LAGEVRIO revenue
• 	Ex-LAGEVRIO, growth of 9% to 10% (11 to 12% ex-FX)
• 	Assumes ~2 ppt FX headwind
Non-GAAP
Gross Margin Rate ~77.0% 	~77.0%
Non-GAAP
Operating Expenses1 	$34.0B to $34.6B 	$39.8B to $40.4B
• 	Includes additional $5.5B related to upfront charge for
the collaboration with Daiichi Sankyo as well as
investment to advance the assets
Other (Income) / Expense 	~$100M of expense 	~$200M of expense • 	Includes updated FX expectations and higher net interest
expense related to the Daiichi Sankyo collaboration
Tax Rate 	~30.5% to 31.5% 	~39.0% to 40.0% • 	Includes ~24.5 ppt impact related to business
development activity
Shares Outstanding 	~2.55B 	~2.55B 	• 	Assumes modest share repurchase
Non-GAAP EPS2 	$2.95 to $3.05 	$1.33 to $1.38
• 	Includes $1.70 one-time charge for the Daiichi Sankyo
collaboration and an additional $0.04 to advance the
assets and finance the transaction
• 	Assumes 6 ppt FX headwind (additional $0.05 headwind)

-- 17 of 31 --

18
Continue to invest in our
pipeline and business while
augmenting our pipeline
with value enhancing
business development
$2.6
$0.9
$1.9
$0.1 $0.5
After-Tax R&D 	CapEx 	Dividends
Paid
Business
Development
(ex-divestitures)
Share Repurchase
$ Billions1
1. Reflects Q3 spend.
Remain committed to balanced capital allocation strategy
Capital allocation order of priority

-- 18 of 31 --

Research Update
Dr. Dean Li
President, Merck Research Laboratories

-- 19 of 31 --

Continuing to advance our oncology strategy
Precision Molecular
Targeting
Impact pathways that
can drive cancer growth
Tissue Targeting
Increase cancer cell
sensitivity with ADCs
and immune-engagers
Immuno-oncology
Boost anti-tumor
immune responses
20

-- 20 of 31 --

21
Broadening and advancing our ADC presence
Data presented at ESMO from Phase 3 study evaluating KEYTRUDA in
combination with enfortumab vedotin in 1L locally advanced or metastatic
urothelial carcinoma
KEYNOTE-A39 /
EV-3023
1. Planning to submit a biologics license application (BLA) in the U.S. by the end of March 2024 based on the Phase 2 HERTHENA-Lung01 data in EGFRm
NSCLC that has progressed after EGFR TKI and platinum-based therapies 2. Shows tumor types currently being studied in various phases of development
3. Trial conducted in collaboration with Seagen and Astellas
Generic Name
Phase 1
CDH6
Ovarian
Target
Status
DS-6000
(R-DXd)
Phase 3 1
HER3
EGFRm NSCLC,
Breast
U3-1402
(HER3-DXd)
Phase 2
B7H3
ES-SCLC, Advanced
Solid Tumors
DS-7300
(I-DXd)
Current Tumor
Types2
Raludotatug
deruxtecan
Patritumab
deruxtecan
Ifinatamab
deruxtecan
MK-2870 	MK-1200 1 additional
clinical asset
Phase 1
Claudin 18.2
GI Tumors
Phase 3
TROP2
NSCLC, Breast
Phase 1
Undisclosed
Undisclosed
Undisclosed
Sacituzumab
tirumotecan
Collaborator Daiichi
Sankyo
Kelun
Biotech
Daiichi
Sankyo
Daiichi
Sankyo
Kelun
Biotech
Kelun
Biotech
Undisclosed

-- 21 of 31 --

Sharing data from our earlier stage oncology program
22
Women’s Cancers
• 	KEYNOTE-671:
• 	Presented positive overall survival
data at ESMO from Phase 3 study
• 	KEYTRUDA is the first and only
anti-PD(L)-1 therapy to
demonstrate statistically
significant improvement in OS
and EFS as perioperative
treatment for resectable stage II,
IIIA or IIIB NSCLC versus pre-
operative chemotherapy
• OS benefit generally consistent
across majority of subgroups
• 	6th KEYTRUDA indication for
NSCLC to receive FDA approval
• 	Presented positive data at
ESMO:
• 	KEYNOTE-756 in patients with
ER+ HER2- breast cancer
• 	KEYNOTE-522 in patients with
high-risk early-stage TNBC
• 	KEYNOTE-A18 in patients with
high-risk locally advanced cervical
cancer
• FDA granted priority review with
target action date of January 20 th
Lung 	Bladder
• 	KEYNOTE-123:
• 	Announced Phase 3 trial
evaluating KEYTRUDA for the
adjuvant treatment of certain
patients with localized muscle-
invasive urothelial carcinoma and
locally advanced urothelial
carcinoma significantly improved
disease-free survival

-- 22 of 31 --

23
Leveraging precision medicine to improve outcomes for patients
1. In collaboration with Taiho and Astex
MK-10841
• 	Presented data at ESMO from
Phase 3 LITESPARK-005 study
for treatment of adults with
previously treated advanced
RCC, which showed statistically
significant and clinically
meaningful improvement in
progression-free survival vs.
everolimus (standard of care)
• 	FDA granted priority review
with target action date of
January 17 th
• 	Proceeding with additional
Phase 3 studies
• 	Presented data at ESMO for
oral KRAS inhibitor as
monotherapy in solid tumors
and in combination with
KEYTRUDA in patients with
metastatic NSCLC whose
tumors harbored KRAS G12C
mutations
WELIREG 	MK-3543
• 	Began enrolling patients in
Phase 3 study evaluating
bomedemstat (LSD1 inhibitor) in
2L essential thrombocythemia

-- 23 of 31 --

Europe 	Japan
• 	Granted approval for KEYNOTE-091 for adjuvant
treatment of certain patients with NSCLC
• 	Granted approval for KEYNOTE-811 for 1L treatment of
patients with certain gastric or gastroesophageal
junction adenocarcinoma
• 	Received approval for Lynparza1 in combination with
abiraterone and prednisone for treatment of certain
adult patients with BRCA-mutated metastatic
castration-resistant prostate cancer based on Phase 3
PROpel study
24
Bringing new cancer treatments to patients around the world
1. In collaboration with AstraZeneca

-- 24 of 31 --

Vaccines 	Cardiometabolic
• 	V116:
• 	STRIDE-3 data will be presented at World Vaccine Congress
West Coast on November 28th
• 	If approved, V116 would be the first pneumococcal conjugate
vaccine designed to address serotypes responsible for the
majority of adult invasive pneumococcal disease
Significant advancements across our broader pipeline and portfolio
• 	Sotatercept:
• 	Presented post-hoc analysis from STELLAR and interim
analysis from SOTERIA, an open label extension study in PAH
• 	FDA granted priority review for Biologics License Application
with target action date of March 26th
• 	Completed submission to EMA in the European Union
• 	MK-0616:
• 	Initiated Phase 3 CORALreef Lipids study in broad patient
population with hypercholesterolemia
• 	Initiated Phase 3 CORALreef HeFH study for patients with
heterozygous familial hypercholesterolemia
• 	Enrollment has begun for CORALreef Outcomes study
measuring time to first occurrence of major atherosclerotic
cardiovascular events in high risk patients
Immunology
• 	MK-7240:
• 	Beginning to enroll patients in Phase 3 study for treatment of
patients with ulcerative colitis
25

-- 25 of 31 --

Q&A
Rob Davis
Chairman & Chief Executive Officer
Caroline Litchfield
Chief Financial Officer
Dr. Dean Li
President, Merck Research Laboratories
Peter Dannenbaum
Vice President, Investor Relations

-- 26 of 31 --

Appendix
27

-- 27 of 31 --

Q3 2023 GAAP financial results summary
28
Q3 2023 	Q3 2022 	Change 	Change Ex-FX
Sales 	$16.0 	$15.0 	+7% 	+9%
Operating Expenses 	$5.8 	$6.9 	-16% 	-16%
Tax Rate 	15.5% 	9.2% 	+6.3pts 	N/A
GAAP EPS 	$1.86 	$1.28 	+45% 	+55%
$ in billions, EPS amounts

-- 28 of 31 --

$10.1
$4.0
$7.3
$13.1
$1.0
$0
$3
$6
$9
$12
$15
After-Tax R&D 	CapEx 	Dividends Paid 	Business
Development
(ex-divestitures)
Share
Repurchase
Capital allocation: Trailing twelve months
~$18B
Over 5 years, including expanding
manufacturing capacity for Oncology, Vaccines,
and Animal Health. Includes >$10B in the U.S.
Billions
$1.76 	$1.80 	$1.84 	$1.88 	$1.92
$2.20
$2.44
$2.60
$2.76
$2.92
$1.40
$1.70
$2.00
$2.30
$2.60
$2.90
$3.20
2014 	2015 	2016 	2017 	2018 	2019 	2020 	2021 	2022 	2023
Dollars per share	
+2% 	+2% 	+2% +2% 	+2%
+11%
+15%
+7%
Over the past 12 months
Capital investments
2023 to 2027
Commitment to the dividend
29
Well positioned balance sheet
with capacity to fund
additional value-enhancing
business development
opportunities
+6%
Order of priority
+6%
E
1. Includes payments reflected in operating cash flow
1

-- 29 of 31 --

Driving value for patients and shareholders by progressing our pipeline
30
Key regulatory milestones
since the last earnings call:
Key data & clinical advancements
since the last earnings call:
• 	In the U.S.:
o FDA accepted for priority review the sNDA for WELIREG for the treatment of patients with advanced
RCC immune checkpoint and anti-angiogenic therapies based on LITESPARK-005
o FDA accepted for priority review the sBLA for KEYTRUDA in combination with concurrent
chemoradiotherapy for the treatment of patients with newly diagnosed high-risk locally advanced
cervical cancer based on KN-A18
o Received FDA approval for KEYTRUDA in the perioperative setting for the treatment of certain
patients with resectable NSCLC based on KN-671
o FDA approved KEYTRUDA for the treatment of adult and pediatric patients with recurrent locally
advanced or metastatic Merkel cell cancer based on KN-017 and KN-913
o FDA accepted for priority review the BLA for sotatercept for the treatment of patients with PAH based
on STELLAR
o FDA approved an expanded indication for ERVEBO for the prevention of disease caused by Zaire
ebolavirus in individuals 12 months of age and older
• 	In the EU:
o Received EMA approval for KEYTRUDA in combination with trastuzumab and chemotherapy as 1L
treatment in patients with HER2-positive advanced gastric or gastroesophageal junction
adenocarcinoma in PD-L1 positive patients based on KN-811
o Received EMA approval for KEYTRUDA in patients with adjuvant NSCLC based on KN-091
o Received positive CHMP opinion for KEYTRUDA in combination with chemotherapy for 1L treatment of
certain patients with locally advanced unresectable or metastatic HER2- gastric or GEJ adenocarcinoma
based on KN-859
o Received EMA approval for an expanded indication for ERVEBO for active immunization of individuals 12
months of age and older to protect against Ebola Virus Disease (EVD) caused by Zaire ebolavirus
• 	In Japan:
o Received approval of Lynparza 1 in certain patients with BRCA-mutated castration-resistant prostate
cancer
o Accepted for review the sJNDA for KEYTRUDA in the perioperative setting for the treatment of
patients with resectable NSCLC based on KN-671
1. In collaboration with AstraZeneca 2. Trial conducted in collaboration with Seagen and Astellas 3. In collaboration with Eisai
4. In collaboration with Moderna 5. In collaboration with Kelun-Biotech 6. In collaboration with Taiho and Astex
• 	Presented data across broad oncology portfolio at ESMO,
including for KEYTRUDA (KN-A392, KN-671, KN-A18, KN-
522, KN-756, KN-811), Lenvima3, Lynparza1, WELIREG
(LITESPARK-005), V940/mRNA-41574 (INT), MK-
2870/SKB2645 (TROP2 ADC) and MK-10846 (KRAS G12C)
• 	Announced Phase 3 KN-123 trial met one of its dual
primary endpoints of disease-free survival for the adjuvant
treatment of patients with localized muscle-invasive
urothelial carcinoma and locally advanced urothelial
carcinoma after surgery
• 	Presented new analyses from studies of sotatercept at
ERS, including post-hoc analysis of right heart
catheterization and echocardiography data from the
STELLAR study and interim analysis of the Phase 3
SOTERIA open-label extension study
• 	Advanced broad pipeline, including:
o Initiated Phase 3 clinical program for MK-0616, an
oral PCSK9 inhibitor
o Poised to initiate Phase 3 trials for V940 4 in NSCLC,
MK-2870 5 in NSCLC and MK-7240 in UC

-- 30 of 31 --

Phase 2 	Phase 3 	Under regulatory review
Oncology
V181
Dengue Virus
Vaccines
Infectious diseases MK-8189 4
Schizophrenia
Neuroscience
Gefapixant (MK-7264)
Cough (US)
PREVYMIS (MK-8228)
Prophylaxis of CMV in kidney transplant patients (EU)
General medicine
General medicine
As of October 26, 2023
Infectious diseases
Oncology 	Oncology
MK-6024 (efinopegdutide)
NASH
MK-8591B (islatravir+MK-8507) 1
HIV-1 Infection
MK-8591D (islatravir+lenacapavir) 2
HIV-1 Infection
KEYTRUDA (MK-3475)
CSCC (EU)
Hepatocellular (EU)
Mesothelioma
Ovarian
SCLC
MK-1026 (nemtabrutinib)
Hematological Malignancies
MK-1308A (quavonlimab
+pembrolizumab)
RCC
MK-7684A (vibostolimab
+pembrolizumab)
Melanoma
NSCLC
SCLC
MK-4280A (favezelimab
+pembrolizumab)
CRC
Hematological Malignancies
LENVIMA (MK-7902)
Esophageal
Gastric
LYNPARZA (MK-7339)
NSCLC
SCLC
WELIREG (MK-6482)
RCC (EU)
TUKYSA (MK-7119)
Breast
CRC
MK-3475A
(pembrolizumab
+hyaluronidase)
NSCLC
V940
Melanoma
MK-8591A
(doravirine+islatravir) 2
HIV-1 Infection
KEYTRUDA (MK-3475)
2L HCC (US)
LA Cervical (US)
Resectable NSCLC (EU, JPN)
1L HER2- Gastric (US, EU, JPN)
1L Biliary (US, EU, JPN)
WELIREG (MK-6482)
Advanced RCC (US)
MK-2060
Thrombosis
MK-5475
Pulmonary Arterial Hypertension
MK-7962 (sotatercept)
Pulmonary Hypertension due to Left
Heart Disease
Cardiovascular
MK-4830
CRC
Esophageal
Melanoma
NSCLC
Ovarian
RCC
SCLC
MK-5684
Prostate
MK-5890 (boserolimab)
NSCLC
SCLC
LYNPARZA (MK-7339)
Advanced Solid Tumors
LENVIMA (MK-7902)
Biliary
HNSCC
Pancreas
Prostate
SCLC
KEYTRUDA (MK-3475)
Advanced Solid Tumors
Prostate
MK-3543
(bomedemstat)
Myeloproliferative
Disorders
MK-4280
(favezelimab)
NSCLC
MK-4280A
(favezelimab+pembroli
zumab)
Bladder
cSCC
Esophageal
Melanoma
RCC
SCLC
WELIREG (MK-6482)
Biliary
Certain VHL tumors (EU)
CRC
Endometrial
Esophageal
HCC
Pancreatic
Rare Cancers
TUKYSA (MK-7119)
Advanced Solid Tumors
Bladder
Biliary
Cervical
Endometrial
Gastric
NSCLC
MK-7684A
(vibostolimab
+pembrolizumab)
Biliary
Bladder
Breast
Cervical
CRC
Endometrial
Esophageal
Gastric
HCC
HNSCC
Ovarian
Prostate
MK-0482
NSCLC
MK-1308 (quavonlimab)
NSCLC
MK-1308A
(quavonlimab
+pembrolizumab)
CRC
SCLC
MK-2140 (zilovertamab
vedotin)
Bladder
Breast
Gastric
Hematological Malignancies
NSCLC
Ovarian
Pancreas
MK-2870
Neoplasm Malignant
Broad and innovative pipeline to address significant unmet medical needs
31
Vaccines
MK-1654 (clesrovimab)
Respiratory Syncytial
Virus (RSV)
1 On FDA clinical hold 2On FDA partial clinical hold for higher doses than those used in current clinical trials	
3 Available in the US under EUA 4 Development is co-funded by Royalty Pharma
Note: Pipeline does not include the three DXd ADCs from the collaboration with Daiichi Sankyo
MK-7962 (sotatercept)
Pulmonary Arterial
Hypertension (EU)
Cardiovascular
V116
Pneumococcal vaccine,
adult
MK-7240
Ulcerative Colitis
Immunology
MK-0616
Hypercholesterolemia
MK-7962 (sotatercept)
Pulmonary Arterial Hypertension (US)
Cardiovascular
LAGEVRIO (MK-4482) 3
COVID-19 antiviral

-- 31 of 31 --